Myosin XVIIIa CRISPR/Cas9 KO Plasmid (m): sc-436163
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Myosin XVIIIa CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Myosin XVIIIa genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Myosin XVIIIa Antibody (H-10): sc-365328
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Myosin XVIIIa CRISPR/Cas9 KO Plasmid (m) | sc-436163 | 20 µg | $397.00 |
Overview
Myo18a encodes myosin XVIIIa, an unconventional actin-based motor/scaffold that localizes to dynamic actin networks and contributes to cytoskeletal organization, membrane remodeling, and cell shape control. Myosin XVIIIa has been linked to processes such as cell migration, adhesion, and intracellular trafficking through coordination of actin filament assembly and contractile structures. In mouse systems, Myo18a function is commonly studied in the context of tissue morphogenesis, neuronal and immune cell motility, and regulation of mechanotransduction pathways. Dysregulated actin–myosin architecture and associated signaling can influence phenotypes relevant to developmental abnormalities and cancer-associated changes in invasion and metastasis biology.
Myosin XVIIIa CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Myo18a gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Myo18a together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Myo18a open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Myosin XVIIIa protein expression.
This CRISPR knockout system enables efficient generation of Myo18a-deficient cell models for investigation of Myosin XVIIIa signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Myo18a exon(s) critical for Myosin XVIIIa function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Myo18a genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Myosin XVIIIa CRISPR/Cas9 KO Plasmid (m) and Myosin XVIIIa CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Myo18a locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Myosin XVIIIa HDR Plasmid (m) and Myosin XVIIIa HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Myo18a homology arms to support homology-directed repair at defined Myo18a target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.